ABBV shares moved higher after the pharmaceutical-maker said it earned $980 million during the first quarter, up 1.2% from $968 million in the prior-year period. Adjusted EPS came in at 71 cents, beating guidance issued earlier this year, Reuters noted.
Quarterly sales climbed to $4.56 billion, up 5.4% over the year-ago period, and topping the $4.33 billion that Wall Street was expecting.
AbbVie said that its first quarter results were boosted by a 18% jump in worldwide sales of its rheumatoid arthritis drug, Humira, the Wall Street Journal noted. During the quarter, global Humira sales hit $2.6 billion.
On Thursday, AbbVie stock closed at $49.32 per share.
More Stocks in the News:
- UA, BEAM: Under Armour to Replace Beam in S&P 500
- CAT: Caterpillar Stock Jumps on Forecast, Profits
- SVU: SuperValu Stock Soars on Earnings Beat